- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
FDA approves no-comb lice treatment
The Food and Drug Administration has approved prescription-strength lotion Sklice (Sanofi Pasteur) for the treatment of head lice in children ages 6 months and older.
Washington - The Food and Drug Administration has approved prescription-strength lotion Sklice (Sanofi Pasteur) for the treatment of head lice in children ages 6 months and older.
In clinical trials, a single, 10-minute application of Sklice, which contains the parasite-killing drug ivermectin 0.5 percent, eliminated lice from 75 percent of the 781 participants after two weeks, with no combing necessary, Time reports.
Less than 1 percent of the participants experienced side effects, which included conjunctivitis, eye irritation, dandruff, dry skin and a burning sensation.
Sanofi says Sklice should be available in the United States in a few months.
Go back to the Dermatology Times eNews newsletter.
